CRO Market and Partner Assessment: Preview Report
A free preview of how ProGen's CRO market and partner assessment is built. It maps CROs in seven tiers, reads recovery from company filings segment by segment, records who owns each partner and since when, grades every capability claim on a four-step evidence scale and brings it together in a ten-criteria partner scorecard. Results are reserved for buyers.
Built to order · Research cut-off: 18 November 2026

What this report answers
- Which CRO segments are recovering, and which are consolidating sites and functions?
- Who owns each candidate partner, and since when?
- How strong is the evidence behind a CRO capability claim?
- What does the public trial registry show about which sponsors name their CRO?
- What does a buyer of the full assessment receive?
2.5% of industry-led trials
1,384 of 54,420 industry-led interventional trials that started from 2015 to 18 November 2026 name one of 61 selected CRO and provider names as a collaborator on ClinicalTrials.gov.
10 criteria
In the partner scorecard, each weighted to the program and each score carrying its evidence step, source and date.
What the analysis establishes
The market in seven tiers
Large integrated CROs, mid-size full-service CROs, specialist CROs, functional service providers, laboratory and bioanalytical providers, early-phase and Phase 1 units, and imaging and core labs. Each CRO carries its ownership and headquarters where public, and its specialties, with one primary tier.
Recovery from the filings
Six signals for 11 listed companies, Q3 2025, Q2 2026 and Q3 2026, where disclosed: net book-to-bill, backlog, cancellations, revenue growth, guidance and headcount. Clinical delivery and the laboratory and early-phase layer are read on different signals.
Ownership and change of control
14 sourced transactions from January 2024 to November 2026, investor owners with their entry dates where confirmed, restructuring, and WARN notices from seven state lists, so a change of control during a study is part of the diligence.
Capability graded by evidence
Radiopharmaceuticals, cell and gene therapy, rare disease, and oncology and ADCs. Every claim sits on one of four steps, from no public evidence to a record anyone can check, with its source and date.
Built to your decision
Each assessment is scoped to the decision in front of you, whether a partner shortlist, a review of an incumbent, a diligence or an investment thesis, and quoted on request.
About this intelligence
More than 250 facts verified at the primary source, each with its source, date and label. Sources include public registries, regulator records, company filings and disclosures. Other sources are proprietary ProGen intelligence sources. Evidence is current to 18 November 2026.
Sponsors selecting or reviewing CRO partners. Investors in CROs and CRO-dependent companies. CRO strategy and business development teams. Corporate development teams assessing CRO acquisitions.
Contents
- Why a CRO assessment
- The questions it answers
- How the assessment is built
- The market in seven tiers
- Recovery, segment by segment
- Ownership and change of control
- Capability, graded by evidence
- What the public registry shows
- Integrated data delivery
- The partner scorecard
- One partner row, values withheld
- Questions to ask before signing
- What a buyer receives
Market tiers covered
Large integrated CROs, Mid-size full-service CROs, Specialist CROs, Functional service providers, Laboratory and bioanalytical, Early-phase and Phase 1 units, Imaging and core labs
The full 7-page briefing is free. Tell us where to send it and it downloads immediately.
CRO Market and Partner Assessment
Built to your question and quoted individually: how the CRO market is moving, and which partners fit your program.
See the analysis →